Nuvectis Pharma (NVCT) Projected to Post Quarterly Earnings on Tuesday

Nuvectis Pharma (NASDAQ:NVCT) will likely be announcing its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of ($0.26) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 7:00 AM ET.

Nuvectis Pharma (NASDAQ:NVCT) last posted its quarterly earnings data on Wednesday, February 11th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.05). On average, analysts expect Nuvectis Pharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nuvectis Pharma Price Performance

NVCT opened at $8.46 on Friday. The company has a market capitalization of $224.11 million, a price-to-earnings ratio of -6.41 and a beta of -0.29. Nuvectis Pharma has a 1-year low of $5.55 and a 1-year high of $11.52. The business has a 50 day moving average price of $8.32 and a two-hundred day moving average price of $7.00.

Hedge Funds Weigh In On Nuvectis Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of NVCT. State Street Corp lifted its position in shares of Nuvectis Pharma by 13.1% in the fourth quarter. State Street Corp now owns 154,666 shares of the company’s stock worth $1,168,000 after purchasing an additional 17,950 shares in the last quarter. Marshall Wace LLP lifted its position in Nuvectis Pharma by 63.6% in the 2nd quarter. Marshall Wace LLP now owns 63,613 shares of the company’s stock worth $475,000 after buying an additional 24,739 shares in the last quarter. Goldman Sachs Group Inc. purchased a new stake in Nuvectis Pharma in the 1st quarter worth approximately $446,000. Jane Street Group LLC acquired a new stake in shares of Nuvectis Pharma during the 1st quarter valued at $413,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Nuvectis Pharma by 15.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 44,022 shares of the company’s stock valued at $332,000 after acquiring an additional 6,040 shares in the last quarter. Institutional investors and hedge funds own 96.77% of the company’s stock.

Analysts Set New Price Targets

NVCT has been the topic of a number of research reports. HC Wainwright reissued a “buy” rating on shares of Nuvectis Pharma in a research note on Wednesday, December 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Nuvectis Pharma in a research report on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $15.33.

About Nuvectis Pharma

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.